Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Abstract To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor T (CAR-T) cells, we developed the FasT CAR-T (F-CAR-T) next-day manufacturing platform. We report the preclinical and first-in-human clinical studies evaluating the safety, feasibility, and prelimina...

Full description

Bibliographic Details
Main Authors: Junfang Yang, Jiaping He, Xian Zhang, Jingjing Li, Zhenguang Wang, Yongliang Zhang, Liyuan Qiu, Qionglu Wu, Zhe Sun, Xun Ye, Wenjie Yin, Wei Cao, Lianjun Shen, Martina Sersch, Peihua Lu
Format: Article
Language:English
Published: Nature Publishing Group 2022-07-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00694-6

Internet

https://doi.org/10.1038/s41408-022-00694-6

Similar Items